Medicus Pharma

Q2 FY2026 EarningsQ2 FY26 missed consensus estimates on profitability as the company accelerated R&D for its Teverelix program. GAAP Net Loss was $11.68M versus the $5.66M expected, leading to a GAAP EPS of -$0.21 compared to the -$0.13 consensus. Operating expenses surged to $11.48M, significantly exceeding implied cost expectations, primarily driven by a 241% YoY increase in R&D and higher stock-based compensation. While the company secured $22.86M in new debt financing to support its Phase 2 pipeline, the higher-than-expected cash burn and substantial share dilution from ATM/SEPA programs remain key concerns for investors.